Market Newsdesk

SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that data from the Company’s ongoing Phase 1a/b clinical trial of bexobrutideg (NX-5948) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia will be presented at two major upcoming scientific conferences.

Data will be featured in two posters at the European Hematology Association 2025 Congress (EHA 2025), taking place June 12–15, 2025, in Milan, Italy, and in an oral presentation and poster at the 18th International Conference on Malignant Lymphoma (18-ICML), to be held June 17–21, 2025, in Lugano, Switzerland.

EHA 2025 Presentation Details:

Title:
Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed refractory CLL: updated findings from an ongoing Phase 1a Study

Presenting author: Zulfa Omer, M.D., Assistant Professor Internal Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH, USA
Session title: Poster Session 1
Session date and time: Friday, June 13 (18:30 – 19:30 CEST)
Abstract ID: PF571

Title: Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, shows high clinical activity and tolerable safety in an ongoing Phase 1a/b study in patients with Waldenström macroglobulinemia
Presenting author: Dima El-Sharkawi, M.B., B.S., M.A., Ph.D., MRCP FRCPath, Consultant Haematologist, Royal Marsden NHS Foundation Trust, Sutton, UK
Session title: Poster Session 2
Session date and time: Saturday, June 14 (18:30 – 19:30 CEST)
Abstract ID: PS1883

18-ICML Oral Presentation Details:

Title:
Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed refractory CLL: updated findings from an ongoing Phase 1a Study

Presenter: Alexey Danilov, M.D., Ph.D., Marianne and Gerhard Pinkus Professor in Early Clinical Therapeutics, Co-Director of Toni Stephenson Lymphoma Center, City of Hope National Medical Center, Duarte, CA, USA
Session title: 18: New Drugs
Session date and time: Saturday, June 21 (9:30 CEST).
Abstract ID: 093

18-ICML Poster Presentation Details:

Title: Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, shows high clinical activity and tolerable safety in an ongoing Phase 1a/b study in patients with Waldenström macroglobulinemia
Presenting author: David Lewis, M.D., Consultant Hematologist, Derriford Hospital; Associate Professor, Derriford Hospital, Plymouth, UK
Session title: Poster Session (Odd numbered posters)
Session date and time: Thursday, June 19 (10:00-18:00 CEST)
Abstract ID: 437

About Bexobrutideg (NX-5948)

Bexobrutideg is an investigational, orally bioavailable, brain penetrant, small molecule degrader of BTK. Bexobrutideg is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies. Additional information on the ongoing clinical trial can be accessed at clinicaltrials.gov (NCT05131022).

About Nurix Therapeutics, Inc.

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix’s partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements regarding the planned timing for the provision of updates and findings from the clinical trial of bexobrutideg at EHA 2025 and ICML 2025, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, the risks described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the quarter ended February 28, 2025, and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect Nurix’s business and results of operations, which could, in turn, have a significant and adverse impact on Nurix’s stock price. Nurix cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nurix undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.

Contacts:

Investors

Kris Fortner.
Nurix Therapeutics, Inc.
[email protected] 

Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
[email protected]

Media

Aljanae Reynolds
Wheelhouse Life Science Advisors
[email protected]

SINGAPORE, May 14, 2025 (GLOBE NEWSWIRE) — Primech Holdings Limited (“Primech” or the “Company”) (Nasdaq: PMEC), an established technology-driven facility services provider in the public and private sectors operating mainly in Singapore, today announced that it has received notice from the Nasdaq Stock Market (“Nasdaq”) on May 13, 2025 informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for continued listing on The Nasdaq Capital Market. 

Primech was previously notified by Nasdaq on May 14, 2024 that it was not in compliance with the minimum bid price rule because its ordinary share failed to meet the closing bid price of $1.00 or more for 30 consecutive business days. In order to regain compliance with the Rule, the Company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days. This requirement was met on May 12, 2025, the tenth consecutive trading day when the closing bid price of the Company’s ordinary share was over $1.00. Therefore, Nasdaq considers the prior bid price deficiency matter now closed.

“We are pleased to have regained compliance with Nasdaq’s listing standards,” said Kin Wai Ho, CEO of Primech Holdings Limited. “This reflects the resilience of our business model and the unwavering dedication of our team. We remain focused on our growth initiatives to expand our market presence in the facility services sector, particularly our AI-powered cleaning technologies.”

About Primech Holdings Limited

Headquartered in Singapore, Primech Holdings Limited is a leading provider of comprehensive technology-driven facilities services, predominantly serving both public and private sectors throughout Singapore. Primech Holdings offers an extensive range of services tailored to meet the complex demands of its diverse clientele. Services include advanced general facility maintenance services, specialized cleaning solutions such as marble polishing and facade cleaning, meticulous stewarding services, and targeted cleaning services for offices and homes. Known for its commitment to sustainability and cutting-edge technology, Primech Holdings integrates eco-friendly practices and smart technology solutions to enhance operational efficiency and client satisfaction. This strategic approach positions Primech Holdings as a leader in the industry and a proactive contributor to advancing industry standards and practices in Singapore and beyond. For more information, visit www.primechholdings.com.     

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, for example, statements about completing the acquisition, anticipated revenues, growth, and expansion. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. These forward-looking statements are also based on assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. Investors can find many (but not all) of these statements by the use of words such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “likely to” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure that such expectations will be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.

Company Contact:
Email: [email protected]

Investor Relations Contact:        
Matthew Abenante, IRC
President                                        
Strategic Investor Relations, LLC                                         
Tel: 347-947-2093
Email: [email protected]

Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations

Early dose-escalation data from Phase 1 CARDINAL study of TERN-701 in CML patients showed compelling molecular responses in patients with heavily pre-treated CML, including deepening responses in patients with poor response to asciminib

Additional safety and efficacy data from CARDINAL, including 6-month major molecular response (MMR) rates expected 4Q 2025

FOSTER CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that preclinical data supporting the potential of TERN-701 as a treatment for chronic myeloid leukemia (CML) will be highlighted in an oral presentation at the 30^th European Hematology Association Congress (EHA25) taking place from June 12-15, 2025 in Milan, Italy.

TERN-701 is an investigational next-generation allosteric BCR-ABL inhibitor specifically targeting the ABL myristoyl pocket. The preclinical data to be presented highlight the potency of TERN-701 on more than 20 clinically relevant resistance mutations in the active-site, P-loop, and allosteric regions of the BCR-ABL oncoprotein, and provide additional data characterizing the drug-like properties of TERN-701 and supporting the potential to provide meaningful clinical benefits over existing therapies.

“We are delighted our abstract has been selected for oral presentation at EHA25. These preclinical data provide further mechanistic insights into the clinical responses we have seen in our ongoing phase 1 study including deepening responses after suboptimal responses to asciminib and other TKIs,” stated Emil Kuriakose, M.D., chief medical officer of Terns Pharmaceuticals. “We are especially encouraged by the greater potency of TERN-701 compared to asciminib against several resistance mutations in the active-site and allosteric domains, implying potential for improved clinical responses with TERN-701 in patients with these mutations and supporting the potential for TERN-701 to be a best in class therapy for CML patients in all lines of therapy.”

Details of the Oral Presentation:

Title:	Characterization & Efficacy of TERN-701 in Pre-Clinical Models of Chronic Myeloid Leukemia
Number:	S169
Session:	Novel Approaches of CML Treatment
Date/Time:	June 13, 2025; 17:00 – 18:15 CEST
Presenter:	Ben Parson, Discovery Scientist, Terns Pharmaceuticals

About TERN-701 and CARDINAL Phase 1 Clinical Trial

TERN-701 is currently being evaluated in the CARDINAL trial (NCT06163430), a global multi-center dose escalation and dose-expansion Phase 1 clinical trial to assess safety, tolerability, and efficacy in patients with previously treated chronic phase (CP) CML. The dose escalation portion of the Phase 1 CARDINAL study completed in January 2025 with no dose limiting toxicities (DLTs) observed up to the maximum dose of 500 mg QD. Terns initiated the dose expansion portion study in April 2025 in which patients will be randomized to one of two dose cohorts (320 mg or 500 mg QD) with up to 40 patients per arm. Additional safety and efficacy data expected in the fourth quarter of 2025 will include a larger cohort of patients with longer durations of treatment and read through to approval endpoint of 6-month major molecular response (MMR).

Previously announced positive interim data from the dose escalation portion of the trial demonstrated compelling molecular responses starting at the lowest dose in heavily pre-treated CML patients with high baseline BCR-ABL transcript levels. It also showed an encouraging safety profile with no dose limiting toxicities, adverse event-related treatment discontinuations or dose reductions across all dose escalation cohorts.

In addition, data on drug-drug interactions (DDIs) from the ongoing healthy volunteer study demonstrate that TERN-701 is not a clinically relevant inhibitor of CYP3A4 or OATB1/3 and, therefore, reduces the potential liability of concomitant medication use and provides additional differentiation from asciminib.   

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: www.ternspharma.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements about the Company within the meaning of the federal securities laws, including statements related to the presentation of positive preclinical data for the treatment of chronic myeloid leukemia at the European Hematology Association Congress; expectations, timing and potential results of the TERN-701 clinical trials and other development activities of the Company and its partners; the potential indications to be targeted by the Company with its small-molecule product candidates; the therapeutic potential of the Company’s small-molecule product candidates; the potential for the mechanisms of action of the Company’s product candidates to be therapeutic targets for their targeted indications; the potential utility and progress of the Company’s product candidates in their targeted indications, including the clinical utility of the data from and the endpoints used in the Company’s clinical trials; the Company’s clinical development plans and activities, including the results of any interactions with regulatory authorities on its programs; the Company’s expectations regarding the profile of its product candidates, including efficacy, tolerability, safety, metabolic stability and pharmacokinetic profile and potential differentiation as compared to other products or product candidates; the Company’s plans for and ability to continue to execute on its current development strategy, including potential combinations involving multiple product candidates; the potential commercialization of the Company’s product candidates; the Company’s plans and expectations around the addition of key personnel; and the Company’s expectations with regard to its cash runway and sufficiency of its cash resources. All statements other than statements of historical facts contained in this press release, including statements regarding the Company’s strategy, future financial condition, future operations, future trial results, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “demonstrate,” highlight,” “may,” “observed,” “provides,” “showed,” “support,” “targeting,” “will,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results and the implementation of the Company’s plans to vary materially, including the risks associated with the initiation, cost, timing, progress, results and utility of the Company’s current and future research and development activities and preclinical studies and clinical trials. These risks are not exhaustive. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2024, and in Terns’ future filings with the SEC. All forward-looking statements in this press release are based on information available to Terns as of the date of this press release, and Terns undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.

Contacts for Terns

Investors

Kaytee Bock Zafereo
[email protected]

Media

Jenna Urban
CG Life
[email protected]

BOSTON, May 14, 2025 (GLOBE NEWSWIRE) — Berman Tabacco announces that a securities class action alleging violations of the Securities Exchange Act of 1934 has been filed against Compass Diversified Holdings (“Compass” or the “Company”) (NYSE: CODI), and others, on behalf of persons or entities who purchased or otherwise acquired publicly traded Compass securities between May 1, 2024, and May 7, 2025, inclusive (the “Class Period”). The case is styled, Matthews v. Compass Group Diversified Holdings, LLC, et. al, No. 25-cv-00981 (C.D. Cal.).

Discuss Your Legal Rights and Options

If you wish to serve as Lead Plaintiff for the Class, you must file a motion to serve as Lead Plaintiff with the Court no later than July 8, 2025. Any member of the proposed class may move the Court to serve as Lead Plaintiff through counsel of their choice or may choose to do nothing and remain a member of the proposed class.

If you purchased Compass securities during the Class Period and sustained significant losses and would like to serve as Lead Plaintiff, please contact us here: Shareholder Contact | Berman Tabacco or contact us at 800-516-9926 or [email protected].

About Berman Tabacco

Since 1982, our firm has prosecuted hundreds of securities cases on behalf of investors. The firm and its attorneys have been recognized for their work on behalf of plaintiffs, including by Benchmark Litigation, which ranked the firm as a Top Plaintiffs’ Firm and as Highly Recommended. Chambers USA recognized the firm as a leading securities litigation firm in its Securities Litigation–Mainly Plaintiff category. The Legal 500 has also ranked the firm as recommended in securities litigation. The firm has offices in Boston, Massachusetts and San Francisco, California.

This notice may constitute attorney advertising.  

Past results do not guarantee future outcomes. 

Jay Eng, Esq.
Berman Tabacco
One Liberty Square
Boston, Massachusetts
(800) 516-9926
Email: [email protected]

• Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteers
• Management will host a corporate update conference call on Monday June 16 at 8:00 am ET / 2:00 pm CEST
  

WATERTOWN, Mass., May 14, 2025 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from multiple programs in its hematology portfolio at the upcoming European Hematology Association (EHA) 2025 Congress, which will be held in Milan, Italy on June 12-15, 2025.

“As we progress toward major company milestones in the second half of 2025, this year’s EHA presentations showcase steady progress across our pipeline,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc. “We plan to share data from the HELIOS long-term extension trial, further supporting bitopertin’s potential profile as the first disease-modifying treatment for EPP. We’ll also present additional durability data and new analyses from the Phase 1b study of DISC-0974 in patients with MF anemia, along with new data from DISC-3405 in healthy volunteers that supports its progression into a Phase 2 study in polycythemia vera in the first half of this year and its broader potential in diseases of iron overload.”

Management will host a call to review the presented data on June 16 at 8:00 am ET. Please register for the event on the Events and Presentations page of Disc’s website (https://ir.discmedicine.com/)

Details of Presentations and Abstracts

The full abstracts are now available through the EHA conference website. Pursuant to Disc Medicine practice, the abstracts published today contain previously presented data, and new data and analyses are reserved for presentation at the conference.

Bitopertin Poster Presentations:

Abstract Number: PS2210
Title: Results from the HELIOS Study: A Phase 2, Open-Label, Long-Term Extension Study of Bitopertin in Erythropoietic Protoporphyria
Date / Time: Saturday, June 14, 6:30 pm CEST / 12:30 pm ET
Presenting Author: Melanie Chin

DISC-0974 Poster Presentations:

Abstract Number:
 PF856
Title: A Phase 1b/2 Study of DISC-0974, An Anti-Hemojuvelin Antibody, In Patients with Myelofibrosis and Anemia
Date / Time: Friday, June 13, 6:30 pm CEST / 12:30 pm ET
Presenting Author: Sima Bhatt

Abstract Number:
 PS1845
Title: DISC-0974 (An Anti-Hemojuvelin Antibody) in Non-Transfusion-Dependent Patients with Myelofibrosis: Laboratory Correlates of Major Anemia Response
Date / Time: Saturday, June 14, 6:30 pm CEST / 12:30 pm ET
Presenting Author: Ayalew Tefferi

Abstract Number:
 PS1814
Title: Anti-Hemojuvelin Monoclonal Antibody Further Enhances Hematologic Response to ESA and/or Luspatercept in Mice
Date / Time: Saturday, June 14, 6:30 pm CEST / 12:30 pm ET
Presenting Author: Min Wu

DISC-3405 Poster Presentations:

Abstract Number: PF1216
Title: An Iron Pulse Study to Assess Oral Iron Absorption Following Treatment with DISC-3405 in Healthy Volunteers
Date / Time: Friday, June 13, 6:30 pm CEST / 12:30 pm ET
Presenting Author: Guowen Liu

Abstract Number: PS2207
Title: Single- and Multiple- Ascending Doses of DISC-3405, A Recombinant Humanized Antibody Targeting TMPRSS6, Increased Hepcidin and Reduced Iron and Hematocrit in Healthy Volunteers
Date / Time: Saturday, June 14, 6:30 pm CEST / 12:30 pm ET
Presenting Author: Marcus Carden

About Disc Medicine

Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.

Disc Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding: Disc’s future product development plans and projected timelines for the presentation of data, initiation and completion of preclinical and clinical trials and other activities. The use of words such as, but not limited to, “believe,” “expect,” “estimate,” “project,” “intend,” “future,” “potential,” “continue,” “may,” “might,” “plan,” “will,” “should,” “seek,” “anticipate,” or “could” or the negative of these terms and other similar words or expressions that are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Disc’s current beliefs, expectations and assumptions regarding the future of Disc’s business, future plans and strategies, clinical results and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Disc may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and investors should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of a number of material risks and uncertainties including but not limited to: the adequacy of Disc’s capital to support its future operations and its ability to successfully initiate and complete clinical trials; the nature, strategy and focus of Disc; the difficulty in predicting the time and cost of development of Disc’s product candidates; Disc’s plans to research, develop and commercialize its current and future product candidates; the timing of initiation of Disc’s planned preclinical studies and clinical trials; the timing of the availability of data from Disc’s clinical trials; Disc’s ability to identify additional product candidates with significant commercial potential and to expand its pipeline in hematological diseases; the timing and anticipated results of Disc’s preclinical studies and clinical trials and the risk that the results of Disc’s preclinical studies and clinical trials may not be predictive of future results in connection with future studies or clinical trials and may not support further development and marketing approval; and the other risks and uncertainties described in Disc’s filings with the Securities and Exchange Commission, including in the “Risk Factors” section of Disc’s Annual Report on Form 10-K for the year ended December 31, 2024, and in subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement speaks only as of the date on which it was made. None of Disc, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law.

Media Contact

Peg Rusconi
Deerfield Group
[email protected]

Investor Relations Contact

Christina Tartaglia
Precision AQ
[email protected]

Salt Lake City, Utah, May 14, 2025 (GLOBE NEWSWIRE) —
Co-Diagnostics, Inc.
(Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that they will be participating in the D. Boral Capital (“DBC”) Inaugural Global Conference on May 14, 2025 in New York City.

The DBC conference connects emerging growth issuers across multiple sectors with institutional investors. Company representatives will be participating in one-on-one meetings to introduce institutions to the Company’s value proposition and to the upcoming Co-Dx PCR* testing platform.

More information about the conference can be found here.

*The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to identify genetic markers for use in applications other than infectious disease.

Please note that we disclaim any responsibility for the content of external links provided in this press release. These links are provided solely for the reader’s convenience and do not constitute an endorsement by the Company.

Company Contact:

Andrew Benson

Head of Investor Relations

+1.801.438.1036

[email protected]

Presentation to Include Updated Data from 17 Sickle Cell Disease Patients in the Ongoing BEACON Phase 1/2 Clinical Trial Evaluating Safety and Efficacy of BEAM-101

Beam to Host Investor Webcast on Friday, June 13, 2025, at 4:00 p.m. ET

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present new data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease (SCD) at the European Hematology Association 2025 Congress (EHA2025), taking place June 12-15, 2025, in Milan, Italy. BEAM-101 is an investigational genetically modified ex vivo cell therapy for the treatment SCD with severe vaso-occlusive crises (VOCs).

“We are excited to share an updated safety and efficacy dataset from 17 patients in the BEACON Phase 1/2 clinical trial at EHA2025, as we continue to build on our understanding of this potentially transformative, one-time treatment for people living with SCD,” said Amy Simon, M.D., chief medical officer of Beam. “SCD affects millions of people worldwide, and we are committed to delivering a potential lifelong treatment that addresses the root cause of this debilitating condition. These new data, along with additional insights from our other presentations at EHA2025, further enhance our understanding of the disease, support a differentiated profile of BEAM-101 and underscore the promise of base editing in creating precision therapies for patients.”

Presentation details are as follows:

BEAM-101 Presentations:

Title: Base Editing for Sickle Cell Disease: Ongoing Results from the BEACON Study Evaluating the Safety and Efficacy of BEAM-101, the First Base-Edited Autologous CD34+ HSPC One-Time Cell Therapy
Abstract: PF1151
Poster Session: Poster Session 1
Session Time: Friday, June 13, 2025, 6:30 – 7:30 p.m. CEST
Presenter: Ashish Gupta, M.D., MPH, University of Minnesota

Title: Red Blood Cell (RBC) Health and Function Post BEAM-101 Treatment: Multiple Exploratory Biomarkers Demonstrate Rheology and Sickling Parameters Comparable to Sickle Cell Trait (SCT)
Abstract: PF1155
Poster Session: Poster Session 1
Session Time: Friday, June 13, 2025, 6:30 – 7:30 p.m. CEST
Presenter: Priya S. Chockalingam, Ph.D., Beam Therapeutics

Title: Integrated Editing and Manufacturing Process Design for BEAM-101, an Autologous CD34+ HSPC Therapy for Sickle Cell Disease, Results in Robust Process Yield and Increased HbF Induction
Abstract: PF1165
Poster Session: Poster Session 1
Session Time: Friday, June 13, 2025, 6:30 – 7:30 p.m. CEST
Presenter: Paul Kopesky, Ph.D., Beam Therapeutics

Collaborator Presentation:

Title: Identifying Potential Biomarkers of Clinical Relevance in Sickle Cell Trait: Interim Findings from the National Alliance of Sickle Cell Centers AUNT Study
Abstract: PF1174
Poster Session: Poster Session 1
Session Time: Friday, June 13, 2025, 6:30 – 7:30 p.m. CEST
Presenter: Julie Kanter, M.D., the University of Alabama at Birmingham

EHA Investor Webcast Information

Beam will host a conference call and webcast on Friday, June 13, 2025, at 4:00 p.m. ET to review key presentations from this year’s EHA meeting. A live webcast of the presentation will be available under “Events” in the Investors section of the company’s website at www.beamtx.com, and a replay will be available shortly after the event.

About BEAM-101

BEAM-101 is an investigational genetically modified cell therapy for the treatment of severe sickle cell disease (SCD). The one-time therapy consists of autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) that have been base-edited in the promotor regions of the HBG1/2 genes and are administered via a hematopoietic stem cell transplant procedure. The BEAM-101 edit is designed to inhibit the transcriptional repressor BCL11A from binding to the promoter without disrupting BCL11A expression, leading to increased production of non-sickling and anti-sickling fetal hemoglobin (HbF) and thus mimicking the effects of naturally occurring variants seen in hereditary persistence of fetal hemoglobin. HbF is the predominant hemoglobin variant during development and early life. The safety and efficacy of BEAM-101 is being evaluated in the ongoing BEACON Phase 1/2 study, an open-label, single-arm, multicenter trial in adult patients with SCD with severe vaso-occlusive crises (VOCs).

About Sickle Cell Disease (SCD)

Sickle cell disease, a severe inherited blood disease, is caused by a single point mutation, E6V, in the beta globin gene. This mutation causes the mutated form of sickle hemoglobin (HbS) to aggregate into long, rigid molecules that bend red blood cells into a sickle shape under conditions of low oxygen. Sickled cells obstruct blood vessels and die prematurely, ultimately resulting in anemia, severe pain (crises), infections, stroke, organ failure and early death. Sickle cell disease is the most common inherited blood disorder in the United States, affecting an estimated 100,000 individuals within the United States and approximately eight million people worldwide.

About Beam Therapeutics

Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements related to: the therapeutic applications and potential of our technology, including with respect to SCD; our plans, and anticipated timing, to advance our BEAM-101 program, including the clinical trial designs and expectations for BEAM-101; our plans to present data at EHA2025; and our ability to develop life-long, curative, precision genetic medicines for patients through base editing. Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the uncertainty that our product candidates will receive regulatory approval necessary to advance human clinical trials; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that initiation and enrollment of, and anticipated timing to advance, our clinical trials may take longer than expected; that our product candidates or the delivery modalities we rely on to administer them may cause serious adverse events; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products; and the other risks and uncertainties identified under the headings “Risk Factors Summary” and “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, our Quarterly Report on Form 10-K for the quarter ended March 31, 2025, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

Contacts:

Investors:
Holly Manning
Beam Therapeutics
[email protected]

Media:
Josie Butler
1AB
[email protected]